Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.52 |
| ▸ | TOP1 | P11387 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487858 | 0.90 | CHRM1 (0.52) | CHRM1TOP1LMNA | |
| SCHEMBL2487860 | 0.79 | CNR2 (0.41) | CHRM1BRD4ALDH1A1 | |
| SCHEMBL2489730 | 0.73 | CHRM1 (0.78) | CHRM1TOP1LMNA | |
| SCHEMBL2487869 | 0.72 | CHRM1 (0.77) | CHRM1TOP1LMNA | |
| SCHEMBL2485884 | 0.72 | CHRM1 (0.69) | CHRM1TOP1LMNA | |
| SCHEMBL2485899 | 0.72 | CHRM1 (0.69) | CHRM1TOP1LMNA | |
| SCHEMBL2485890 | 0.70 | CHRM1 (0.56) | CHRM1TOP1LMNA | |
| SCHEMBL2488333 | 0.70 | CHRM1 (0.66) | CHRM1TOP1 | |
| SCHEMBL2488856 | 0.70 | CHRM1 (0.66) | CHRM1TOP1KDM4EALDH1A1 | |
| SCHEMBL2487134 | 0.70 | CHRM1 (0.71) | CHRM1TOP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | claimed |
| EP-2037739-B1 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-26 | — | — | EP | claimed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | claimed |
| EP-2037739-A2 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck & Co., Inc. (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2008002621-A2 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2008-01-03 | — | — | WO | claimed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2037739-B1 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| WO-2008002621-A2 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | CHRM1, OPRL1, MTNR1A | CHRM1 1/4885TOP1 3853/4885LMNA 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.